

Press Release

Astellas Receives “2021 Award for Excellence in Corporate Disclosure” from the Securities Analysts Association of Japan

TOKYO, October 20, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the company has ranked first in the pharmaceuticals sector for the “2021 Award for Excellence in Corporate Disclosure” granted by the Securities Analysts Association of Japan (SAAJ) to promote the quality and fairness of corporate disclosure.

Astellas was highly evaluated mainly in the following areas:

- Significant improvement in IR stance, with the top management’s proactive information dissemination and engagement in dialogue
- IR group has sufficient accumulated information, and securities analysts and institutional investors are having a useful dialogue with IR personnel
- Announcement of a medium-term plan (“Corporate Strategic Plan 2021” ^{*1}), a full explanation of subsequent progress with concrete measures for achievement, and a capital allocation policy
- Stock market needs are incorporated into the disclosure materials of the medium-term plan

Astellas’ raison d’être is “to contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.” With research and development at the heart of the company, Astellas constantly takes on challenges to deliver innovative new drugs and medical solutions by leveraging its core capabilities. In addition, Astellas aims to sustainably enhance its enterprise value by being chosen and trusted by all the stakeholders including customers, shareholders, employees and community.

Upon receiving the award, Kenji Yasukawa, President and CEO, Astellas, stated as follows:

“Our disclosure philosophy is to make our products on the market and the clinical trial results known in a timely and appropriate manner, as well as proactively explain to the stakeholders not only the features of the projects under research and development, but also the potential impact on society when they are launched. In addition, we strive to make the opportunity to provide information flexibly in line with

the requests and needs of the stakeholders so that we do not unilaterally disseminate information. As a result of these efforts, we believe that we were able to improve the perception of our advocacy activities and our disclosure philosophy, which led to this recognition.”

Astellas will continue to disclose information in a timely, appropriate, and fair manner, as well as proactively engage in dialogue with stakeholders and further improve transparency. Astellas will continue to strive to enhance and improve the quality of its disclosure.



2021 Award for Excellence in Corporate Disclosure

— Industries —



The Securities Analysts
Association of Japan

For details on regarding the “Excellence in Corporate Disclosure,” please refer to the website of the SAAJ (<https://www.saa.or.jp/english/research/disclosure.html>).

*1: Astellas Corporate website “Corporate Strategic Plan 2021”. Available at:
<https://www.astellas.com/jp/en/about/csp2021>

About Astellas

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+® healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at <https://www.astellas.com/en>.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management’s current assumptions and

beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Advocacy & Relations
TEL: +81-3-3244-3201